Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 2/20 | 0.51 |
| ▸ | LGALS8 | O00214 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.39 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14641263 | 1.00 | FGF1 (0.51) | FGF1LGALS8CA1CA2CA9 | |
| SCHEMBL7533461 | 0.91 | LGALS8 (0.57) | FGF1LGALS8CA1CA2CA9 | |
| SCHEMBL7533468 | 0.91 | LGALS8 (0.57) | FGF1LGALS8CA1CA2CA9 | |
| SCHEMBL28577159 | 0.84 | LGALS8 (0.47) | FGF1LGALS8F10 | |
| SCHEMBL25505005 | 0.84 | FGF1 (0.53) | FGF1LGALS8CA1CA2CA9 | |
| SCHEMBL25504956 | 0.84 | FGF1 (0.53) | FGF1LGALS8CA1CA2CA9 | |
| SCHEMBL7121030 | 0.83 | LGALS8 (0.47) | FGF1LGALS8CA1CA2CA9 | |
| SCHEMBL7121026 | 0.83 | LGALS8 (0.47) | FGF1LGALS8CA1CA2CA9 | |
| SCHEMBL30099086 | 0.81 | CA2 (0.43) | FGF1LGALS8CA2LGALS3MAPT | |
| SCHEMBL19594012 | 0.80 | FGF1 (0.51) | FGF1LGALS8F10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140135403-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES | WARATAH PHARMACEUTICALS INC. (CA) | 2014-05-15 | — | — | US | disclosed |
| EP-2656839-A1 | Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases | Waratah Pharmaceuticals, Inc. (CA) | 2013-10-30 | — | — | EP | disclosed |
| US-20110105626-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | MCLAURIN JOANNE | 2011-05-05 | — | — | US | disclosed |
| US-20100331267-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | MCLAURIN JOANNE | 2010-12-30 | — | — | US | disclosed |
| US-20100292157-A1 | Combination Treatments for Alzheimer's Disease and Similar Diseases | WARATAH PHARMACEUTICALS INC. (CA) | 2010-11-18 | — | — | US | disclosed |
| US-20100173960-A1 | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases | WARATAH PHARMACEUTICALS INC. (CA) | 2010-07-08 | — | — | US | disclosed |
| US-20100168250-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASE | WARATAH PHARMACEUTICALS INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100144891-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | MCLAURIN JOANNE | 2010-06-10 | — | — | US | disclosed |
| US-20100113613-A1 | CYCLOHEXANE POLYALCOHOL FORMULATION FOR TREATMENT OF DISORDERS OF PROTEIN AGGREGATION | WARATAH PHARMACEUTICALS (CA) | 2010-05-06 | — | — | US | disclosed |
| WO-2008061373-A1 | COMBINATION TREATMENTS FOR ALZHEIMER'S DISEASE AND SIMILAR DISEASES | WARATAH PHARMACEUTICALS INC. (CA) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008034244-A1 | THE COMBINATION OF A CYCLOHEXANEHEXOL AND A NSAID FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARATAH PHARMACEUTICALS INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007119108-A2 | INOSITOL DERIVATIVES AND THEIR USES IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007101353-A1 | A CYCLOHEXANE POLYALCOHOL FORMULATION FOR TREATMENT OF DISORDERS OF PROTEIN AGGREGATION | WARATAH PHARMACEUTICALS INC. (CA) | 2007-09-13 | — | — | WO | disclosed |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| WO-2007041855-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERISED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS, INC. (CA) | 2007-04-19 | — | — | WO | disclosed |
| US-7148001-B2 | In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases | UNIVERSITY OF WASHINGTON (US) | 2006-12-12 | — | — | US | disclosed |
| US-20020168753-A1 | In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of Alzheimer's and Prion diseases | NATIONAL INSTITUTES OF HEALTH | 2002-11-14 | — | — | US | disclosed |
| EP-1251837-A2 | COMPOUNDS AND METHODS FOR MODULATING CEREBRAL AMYLOID ANGIOPATHY | Neurochem, Inc. (CA) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001085093-A2 | COMPOUNDS AND METHODS FOR MODULATING CEREBRAL AMYLOID ANGIOPATHY | NEUROCHEM, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331267-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | SNCA, PARK7, PMP22 | FGF1 4196/4885LGALS8 1007/4885CA1 2680/4885 |
| US-20110105626-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | CDR2, HYPK, HTT | FGF1 4125/4885LGALS8 3076/4885CA1 4311/4885 |
| US-20100168250-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASE | APP, IAPP, TTR | FGF1 2569/4885LGALS8 965/4885CA1 1492/4885 |
| US-20100292157-A1 | Combination Treatments for Alzheimer's Disease and Similar Diseases | APP, PSEN1, BACE1 | FGF1 1706/4885LGALS8 1205/4885CA1 699/4885 |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | SCLY, SMOX, SMS | FGF1 4396/4885LGALS8 1705/4885CA1 2317/4885 |
| US-20100173960-A1 | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases | HTT, APP, PSEN2 | FGF1 3883/4885LGALS8 2494/4885CA1 1175/4885 |
| US-20140135403-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES | APP, IAPP, TTR | FGF1 2527/4885LGALS8 888/4885CA1 1602/4885 |
| US-20100144891-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SOD1, SOD3, SMN1; SMN2 | FGF1 2728/4885LGALS8 903/4885CA1 487/4885 |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | SCLY, SCO2, SGMS2 | FGF1 4860/4885LGALS8 1044/4885CA1 3722/4885 |
| US-20100113613-A1 | CYCLOHEXANE POLYALCOHOL FORMULATION FOR TREATMENT OF DISORDERS OF PROTEIN AGGREGATION | APP, MAPT, HTT | FGF1 3539/4885LGALS8 2112/4885CA1 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.